Conference Proceedings

The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative

Allison Barraclough, Edward Yoo, Chan Y Cheah, Dipti Talaulikar, Bianca Nguyen, Michelle Turner, Fatima Tahir, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M Johnston, Michael Dickinson, Stephen Opat, Zoe McQuilten, Erica M Wood, Gayathri St George, Cameron Wellard, Eliza A Hawkes

BLOOD | AMER SOC HEMATOLOGY | Published : 2019


Background The time to treatment initiation is determined by tumour burden in patients with follicular lymphoma (FL). The Groupe d'Etude des Lymphomes Folliculaires ('GELF') criteria, defined in the pre-rituximab era, are commonly used to assess tumour burden.2 Patients must meet ≥1 of the following criteria to be considered "high" tumour burden according to GELF: any tumour mass >7 cm; ≥ 3 nodal sites (each >3 cm); B symptoms; splenomegaly; compression syndrome; pleural/peritoneal effusion; leukemic phase or cytopenias. Low tumour burden FL is often excluded from clinical trials, based on data from initial retrospective studies and later randomis..

View full abstract